Access to anti-retroviral drugs, female in Togo

Togo: Access to anti-retroviral drugs, female was 96.0% in 2024. ◆ Volatile

Latest (2024)
96.0%
Change on year
up 2.1%
World rank
14th
of 141 countries
All-time high
96.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Togo, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 1 %2004: 2 %2005: 5 %2006: 6 %2007: 7 %2008: 10 %2009: 15 %2010: 24 %2011: 28 %2012: 36 %2013: 41 %2014: 44 %2015: 50 %2016: 61 %2017: 73 %2018: 74 %2019: 85 %2020: 90 %2021: 90 %2022: 86 %2023: 94 %2024: 96 %

Source: UNAIDS estimates. Measured in %.

Analysis

Togo recorded 96.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 2.1% on the previous year and up 118.2% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Togo peaked at 96.0% in 2024 and was at its lowest, 0.0%, in 2000.

Togo ranks 14th of 141 countries on this measure, in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Togo, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Togo, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 1.0%
2004 2.0% +100.0%
2005 5.0% +150.0%
2006 6.0% +20.0%
2007 7.0% +16.7%
2008 10.0% +42.9%
2009 15.0% +50.0%
2010 24.0% +60.0%
2011 28.0% +16.7%
2012 36.0% +28.6%
2013 41.0% +13.9%
2014 44.0% +7.3%
2015 50.0% +13.6%
2016 61.0% +22.0%
2017 73.0% +19.7%
2018 74.0% +1.4%
2019 85.0% +14.9%
2020 90.0% +5.9%
2021 90.0% +0.0%
2022 86.0% -4.4%
2023 94.0% +9.3%
2024 96.0% +2.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.6% 0.0% 15.0% 10
2010s 51.6% 24.0% 85.0% 10
2020s 91.2% 86.0% 96.0% 5

Countries ranked near Togo

  1. 12 Rwanda 97.0% compare
  2. 12 United Arab Emirates 97.0% compare
  3. 14 Liberia 96.0% compare
  4. 14 Sweden 96.0% compare
  5. 14 United Kingdom of Great Britain and Northern Ireland 96.0% compare
  6. 14 Zambia 96.0% compare

See the full ranking of 160 places →

More gender data for Togo

All data for Togo →

Frequently asked questions

What is access to anti-retroviral drugs, female in Togo?
Access to anti-retroviral drugs, female in Togo was 96.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Togo?
The highest recorded value was 96.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Togo?
The lowest recorded value was 0.0% in 2000.
How does Togo rank for access to anti-retroviral drugs, female?
Togo ranks 14th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Togo?
Over the last ten years it is up 118.2%. The long-run trend across the full record is volatile.
Where does this Togo data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Togo. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/togo/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/togo/">Access to anti-retroviral drugs, female in Togo</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.